Passive immunization with influenza haemagglutinin specific monoclonal antibodies

References

• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet. 2018;391:1285–1300. doi:10.1016/S0140-6736(17)33293-2
   Google Scholar
• Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 2005;3:591–600. doi:10.1038/nrmicro1208. PMID:16064053.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007;4:e178. doi:10.1371/journal.pmed.0040178. PMID:17535101.
   PubMed Web of Science ®Google Scholar
• Yang Q, Shi W, Zhang L, Xu Y, Xu J, Li S, et al. Westward spread of highly pathogenic avian influenza A(H7N9) virus among humans, China. Emerg Infect Dis. 2018;24:1095–98. PMID:29619922.
   PubMed Web of Science ®Google Scholar
• Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol. 2011;9:590–603. doi:10.1038/nrmicro2613. PMID:21747392.
   PubMed Web of Science ®Google Scholar
• Hashem AM. Prospects of HA-based universal influenza vaccine. Biomed Res Int. 2015;2015:414637. doi:10.1155/2015/414637. PMID:25785268.
   PubMed Web of Science ®Google Scholar
• Xia J, Cui JQ, He X, Liu YY, Yao KC, Cao SJ, Han XF, Huang Y. Genetic and antigenic evolution of H9N2 subtype avian influenza virus in domestic chickens in southwestern China, 2013–2016. PLoS One. 2017;12:e0171564. doi:10.1371/journal.pone.0171564. PMID:28158271.
   PubMed Web of Science ®Google Scholar
• Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A. 2012;109:4269–74. doi:10.1073/pnas.1116200109. PMID:22371588.
   PubMed Web of Science ®Google Scholar
• Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9:e1003657. doi:10.1371/journal.ppat.1003657. PMID:24130481.
   PubMed Web of Science ®Google Scholar
• Kim H, Webster RG, Webby RJ. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol. 2018;31:174–83. doi:10.1089/vim.2017.0141.
   Web of Science ®Google Scholar
• Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Oliver G, Pybus SKM, Cheung CL, Raghwani J, Bhatt S, Malik Peiris JS, Guan Y, Rambaut A Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459:1122–5. doi:10.1038/nature08182.
   Web of Science ®Google Scholar
• Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982;31:417–27. doi:10.1016/0092-8674(82)90135-0. PMID:6186384.
   PubMed Web of Science ®Google Scholar
• Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981;289:373–8. doi:10.1038/289373a0. PMID:6162101.
   PubMed Web of Science ®Google Scholar
• Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, McClain MT, Denny TN, Chen X, Munshaw S, Marshall DJ, et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One. 2011;6:e25797. doi:10.1371/journal.pone.0025797. PMID:22039424.
   PubMed Web of Science ®Google Scholar
• Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol. 1993;67:2552–8. PMID:7682624.
   PubMed Web of Science ®Google Scholar
• Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 2011;52:1003–9. doi:10.1093/cid/cir121. PMID:21460314.
   PubMed Web of Science ®Google Scholar
• Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012;337:1343–8. doi:10.1126/science.1222908. PMID:22878502.
   PubMed Web of Science ®Google Scholar
• Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A. 2012;109:9047–52. doi:10.1073/pnas.1118979109. PMID:22615367.
   PubMed Web of Science ®Google Scholar
• Corti D, Suguitan AL, Jr., Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010;120:1663–73. doi:10.1172/JCI41902. PMID:20389023.
   PubMed Web of Science ®Google Scholar
• Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R, Agrati C, Squarcione S, Ippolito G, Puro V, et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis. 2008;14:121–8. doi:10.3201/eid1401.061283. PMID:18258091.
   PubMed Web of Science ®Google Scholar
• Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10:871–5. doi:10.1038/nm1080. PMID:15247913.
   PubMed Web of Science ®Google Scholar
• Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453:667–71. doi:10.1038/nature06890. PMID:18449194.
   PubMed Web of Science ®Google Scholar
• Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208:181–93. doi:10.1084/jem.20101352. PMID:21220454.
   PubMed Web of Science ®Google Scholar
• Henry Dunand CJ, Leon PE, Huang M, Choi A, Chromikova V, Ho IY, Tan GS, Cruz J, Hirsh A, Zheng NY, et al. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe. 2016;19:800–13. doi:10.1016/j.chom.2016.05.014. PMID:27281570.
   PubMed Web of Science ®Google Scholar
• Andrews SF, Graham BS, Mascola JR, McDermott AB. Is It Possible to Develop a “Universal” Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. Cold Spring Harb Perspect Biol. 2017. doi:10.1101/cshperspect.a029413. PMID:28663207.
   PubMed Web of Science ®Google Scholar
• Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A. 2014;111:13133–8. doi:10.1073/pnas.1414070111. PMID:25157133.
   PubMed Web of Science ®Google Scholar
• Henry Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, Huang M, Qu X, Huang Y, Salgado-Ferrer M, et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest. 2015;125:1255–68. doi:10.1172/JCI74374. PMID:25689254.
   PubMed Web of Science ®Google Scholar
• Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M, Horowitz M, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A. 2008;105:5986–91. doi:10.1073/pnas.0801367105. PMID:18413603.
   PubMed Web of Science ®Google Scholar
• Hoa le NM, Mai le Q, Bryant JE, Thai PQ, Hang Nle K, Yen NT, Duong TN, Thoang DD, Horby P, Werheim HF, et al. Association between Hemagglutinin Stem-Reactive Antibodies and Influenza A/H1N1 Virus Infection during the 2009 Pandemic. J Virol. 2016;90:6549–56. doi:10.1128/JVI.00093-16. PMID:27170747.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio. 2016;7:e01996–15. doi:10.1128/mBio.01996-15. PMID:26787832.
   PubMed Web of Science ®Google Scholar
• Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med. 2013;5:198ra07. doi:10.1126/scitranslmed.3006637.
   Web of Science ®Google Scholar
• Raymond DD, Bajic G, Ferdman J, Suphaphiphat P, Settembre EC, Moody MA, Schmidt AG, Harrison SC. Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proc Natl Acad Sci U S A. 2018;115:168–73. doi:10.1073/pnas.1715471115. PMID:29255041.
   PubMed Web of Science ®Google Scholar
• Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 2011;108:14216–21. doi:10.1073/pnas.1111497108. PMID:21825125.
   PubMed Web of Science ®Google Scholar
• Lee PS, Ohshima N, Stanfield RL, Yu W, Iba Y, Okuno Y, Kurosawa Y, Wilson IA. Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun. 2014;5:3614. doi:10.1038/ncomms4614. PMID:24717798.
   PubMed Web of Science ®Google Scholar
• Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. World Health Organization. Smallpox and its eradication. 1988:1371–1409.
   Google Scholar
• WHO. Global Polio Eradication Initiative: annual report 2016. Geneva, Switzerland (WHO/Polio/17.03). 2017.
   Google Scholar
• Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, et al. Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. Cell. 2016;166:596–608. doi:10.1016/j.cell.2016.05.073. PMID:27453466.
   PubMed Web of Science ®Google Scholar
• Paules CI, Lakdawala S, McAuliffe JM, Paskel M, Vogel L, Kallewaard NL, Zhu Q, Subbarao K. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses. J Infect Dis. 2017;216:356–65. doi:10.1093/infdis/jix292. PMID:28633457.
   PubMed Web of Science ®Google Scholar
• O'Donnell CD, Vogel L, Wright A, Das SR, Wrammert J, Li GM, McCausland M, Zheng NY, Yewdell JW, Ahmed R, et al. Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice. MBio. 2012;3. doi:10.1128/mBio.00120-12. PMID:22647789.
   PubMed Web of Science ®Google Scholar
• Bangaru S, Nieusma T, Kose N, Thornburg NJ, Finn JA, Kaplan BS, King HG, Singh V, Lampley RM, Sapparapu G, et al. Recognition of influenza H3N2 variant virus by human neutralizing antibodies. JCI Insight. 2016;1. doi:10.1172/jci.insight.86673. PMID:27482543.
   PubMed Web of Science ®Google Scholar
• Hong M, Lee PS, Hoffman RM, Zhu X, Krause JC, Laursen NS, Yoon SI, Song L, Tussey L, Crowe JE, Jr., et al. Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. J Virol. 2013;87:12471–80. doi:10.1128/JVI.01388-13. PMID:24027321.
   PubMed Web of Science ®Google Scholar
• Xu R, Krause JC, McBride R, Paulson JC, Crowe JE, Jr., Wilson IA. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol. 2013;20:363–70. doi:10.1038/nsmb.2500. PMID:23396351.
   PubMed Web of Science ®Google Scholar
• Lang S, Xie J, Zhu X, Wu NC, Lerner RA, Wilson IA. Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem. Cell Rep. 2017;20:2935–43. doi:10.1016/j.celrep.2017.08.084. PMID:28930686.
   PubMed Web of Science ®Google Scholar
• Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014;88:13580–92. doi:10.1128/JVI.02289-14. PMID:25210195.
   PubMed Web of Science ®Google Scholar
• Lee PS, Wilson IA. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr Top Microbiol Immunol. 2015;386:323–41. PMID:25037260.
   PubMed Web of Science ®Google Scholar
• Lee J, Boutz DR, Chromikova V, Joyce MG, Vollmers C, Leung K, Horton AP, DeKosky BJ, Lee CH, Lavinder JJ, et al. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med. 2016;22:1456–64. doi:10.1038/nm.4224. PMID:27820605.
   PubMed Web of Science ®Google Scholar
• Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Gillespie RA, Kanekiyo M, et al. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. 2016;166:609–23. doi:10.1016/j.cell.2016.06.043. PMID:27453470.
   PubMed Web of Science ®Google Scholar
• Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009;16:265–73. doi:10.1038/nsmb.1566. PMID:19234466.
   PubMed Web of Science ®Google Scholar
• Harris AK, Meyerson JR, Matsuoka Y, Kuybeda O, Moran A, Bliss D, Das SR, Yewdell JW, Sapiro G, Subbarao K, et al. Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A. 2013;110:4592–7. doi:10.1073/pnas.1214913110. PMID:23460696.
   PubMed Web of Science ®Google Scholar
• Tran EE, Podolsky KA, Bartesaghi A, Kuybeda O, Grandinetti G, Wohlbold TJ, Tan GS, Nachbagauer R, Palese P, Krammer F, et al. Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. MBio. 2016;7:e00257. doi:10.1128/mBio.00257-16. PMID:27006464.
   PubMed Web of Science ®Google Scholar
• Verbonitz MW, Ennis FA, Hicks JT, Albrecht P. Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection. J Exp Med. 1978;147:265–70. doi:10.1084/jem.147.1.265. PMID:627837.
   PubMed Web of Science ®Google Scholar
• Quinnan GV, Ennis FA, Tuazon CU, Wells MA, Butchko GM, Armstrong R, McLaren C, Manischewitz JF, Kiley S. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun. 1980;30:362–9. PMID:7439982.
   PubMed Web of Science ®Google Scholar
• Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wrammert J, Wilson PC, Ennis FA. Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol. 2011;85:13463–7. doi:10.1128/JVI.05193-11. PMID:21994454.
   PubMed Web of Science ®Google Scholar
• Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc-FcgammaR interactions in IgG-mediated microbial neutralization. J Exp Med. 2015;212:1361–9. doi:10.1084/jem.20151267. PMID:26282878.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med. 2014;20:143–51. doi:10.1038/nm.3443. PMID:24412922.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest. 2016;126:605–10. doi:10.1172/JCI84428. PMID:26731473.
   PubMed Web of Science ®Google Scholar
• He W, Tan GS, Mullarkey CE, Lee AJ, Lam MM, Krammer F, Henry C, Wilson PC, Ashkar AA, Palese P, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A. 2016;113:11931–6. doi:10.1073/pnas.1609316113. PMID:27698132.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol. 2014;88:13260–8. doi:10.1128/JVI.02133-14. PMID:25210189.
   PubMed Web of Science ®Google Scholar
• Kirchenbaum GA, Carter DM, Ross TM. Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies. J Virol. 2015;90:1116–28. doi:10.1128/JVI.02372-15. PMID:26559834.
   PubMed Web of Science ®Google Scholar
• Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010;6:e1000796. doi:10.1371/journal.ppat.1000796. PMID:20195520.
   PubMed Web of Science ®Google Scholar
• Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, Garcia-Sastre A, Moran TM, Palese P. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A. 2010;107:18979–84. doi:10.1073/pnas.1013387107. PMID:20956293.
   PubMed Web of Science ®Google Scholar
• Koday MT, Nelson J, Chevalier A, Koday M, Kalinoski H, Stewart L, Carter L, Nieusma T, Lee PS, Ward AB, et al. A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. PLoS Pathog. 2016;12:e1005409. doi:10.1371/journal.ppat.1005409. PMID:26845438.
   PubMed Web of Science ®Google Scholar
• Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, Sarma SP, Flynn JA, Temperton NJ, Liang X, et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A. 2014;111:E2514–23. doi:10.1073/pnas.1402766111. PMID:24927560.
   PubMed Web of Science ®Google Scholar
• Boon AC, deBeauchamp J, Hollmann A, Luke J, Kotb M, Rowe S, Finkelstein D, Neale G, Lu L, Williams RW, et al. Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J Virol. 2009;83:10417–26. doi:10.1128/JVI.00514-09. PMID:19706712.
   PubMed Web of Science ®Google Scholar
• Goff PH, Eggink D, Seibert CW, Hai R, Martinez-Gil L, Krammer F, Palese P. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One. 2013;8:e79194. doi:10.1371/journal.pone.0079194. PMID:24223176.
   PubMed Web of Science ®Google Scholar
• Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 2009;5:e1000642. doi:10.1371/journal.ppat.1000642. PMID:19888339.
   PubMed Web of Science ®Google Scholar
• Nesspor TC, Scallon B. Chimeric antibodies with extended half-life in ferrets. Influenza Other Respir Viruses. 2014;8:596–604. doi:10.1111/irv.12273. PMID:25074755.
   PubMed Web of Science ®Google Scholar
• Sutton TC, Lamirande EW, Bock KW, Moore IN, Koudstaal W, Rehman M, Weverling GJ, Goudsmit J, Subbarao K. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017;91:e01603–17.
   Web of Science ®Google Scholar
• Czako R, Vogel L, Lamirande EW, Bock KW, Moore IN, Ellebedy AH, Ahmed R, Mehle A, Subbarao K. In Vivo Imaging of Influenza Virus Infection in Immunized Mice. MBio. 2017;8:pii: e00714–17.
   Web of Science ®Google Scholar
• Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One. 2008;3:e3942. doi:10.1371/journal.pone.0003942. PMID:19079604.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324:246–51. doi:10.1126/science.1171491. PMID:19251591.
   PubMed Web of Science ®Google Scholar
• Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, Friesen RH, Goudsmit J. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J Infect Dis. 2009;200:1870–3. doi:10.1086/648378. PMID:19911992.
   PubMed Web of Science ®Google Scholar
• Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One. 2010;5:e9106. doi:10.1371/journal.pone.0009106. PMID:20161706.
   PubMed Web of Science ®Google Scholar
• Nilsson UR, Muller-Eberhard HJ. Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med. 1967;125:1–16. doi:10.1084/jem.125.1.1. PMID:4959665.
   PubMed Web of Science ®Google Scholar
• Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76:519–29. doi:10.1016/0092-8674(94)90115-5. PMID:8313472.
   PubMed Web of Science ®Google Scholar
• Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, et al. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One. 2013;8:e80034. doi:10.1371/journal.pone.0080034. PMID:24348996.
   PubMed Web of Science ®Google Scholar
• Sautto GA, Kirchenbaum GA, Ross TM. Towards a universal influenza vaccine: different approaches for one goal. Virol J. 2018;15:17. doi:10.1186/s12985-017-0918-y. PMID:29370862.
   PubMed Web of Science ®Google Scholar
• Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE, Jr. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol. 2011;85:10905–8. doi:10.1128/JVI.00700-11. PMID:21849447.
   PubMed Web of Science ®Google Scholar
• He F, Kumar SR, Syed Khader SM, Tan Y, Prabakaran M, Kwang J. Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res. 2013;100:207–14. doi:10.1016/j.antiviral.2013.08.003.
   Google Scholar